Complement C9 Monoclonal Antibody (C9 53) | Invitrogen ABS 004-53-02 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

Complement C9 Monoclonal Antibody (C9 53)

catalog :

ABS 004-53-02

quantity :

400 uL

price :

US 844.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

C9 53

reactivity :

human

product information

Product Type :

Antibody

Product Name :

Complement C9 Monoclonal Antibody (C9 53)

Catalog # :

ABS 004-53-02

Quantity :

400 uL

Price :

US 844.00

Clonality :

Monoclonal

Purity :

Protein A/G

Host :

Mouse

Reactivity :

Human

Applications :

ELISA: 1:20,000

Species :

Human

Clone :

C9 53

Isotype :

IgG1, kappa

Storage :

4 C, store in dark

Description :

C5b-9 membrane attack complexes are assembled from five precursor molecules in the serum. Proteolytic cleavage of C5 by C5 convertase generates C5b which initiates assembly of the C5b-9 complex. The last step of C5b-9 complex formation involves polymerization of C9 which accompanies insertion of the complex into the cell membrane. During formation of C5b-8 and C9 polymerization, neoantigens are generated which are unique to the C5b-9 complex and are not present on any of the individual native complex components. The complement regulatory proteins CD59 and complement S-protein can both prevent C5b-9 insertion into the cell membrane. The formed SC5b-9 complex is unable to attach to cells and is cytolytically inactive. C5b-9 is involved in the progression of chronic proteinuric renal disease by mediating continuous tubulointerstitial damage. Early tubulointerstitial injury in the remnant kidney can be improved when C5b-9 complex forming is abrogated.

Immunogen :

Complement component C9.

Format :

Liquid

Applications w/Dilutions :

ELISA: 1:20,000

Aliases :

ARMD15; C9; C9D; complement C9; complement component 9; complement component C9; Complement component C9a; Complement component C9b; complement protein C9; complement protein C9 precursor